Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's drug side effect targeted by antioxidant NAC – but trial stalls

NCT ID NCT03146130

Symptom relief Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether N-acetylcysteine (NAC), an antioxidant, could help reduce impulse control disorders caused by Parkinson's medications. Only 14 people with mild-to-moderate symptoms were enrolled before the trial was stopped early. The goal was to see if 10 weeks of NAC improved behavior scores compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
N-acetylcysteine (NAC)
What this could lead to
If it worked, NAC could offer a way to ease impulse control problems caused by Parkinson's drugs, improving daily life for some patients.
What could go wrong
The trial was terminated early and very small (14 people), so results are not reliable. NAC may not work for this purpose, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

14 people

The number who actually took part.

Started

Jan 2019

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Parkinson's disease according to UKPDSBB criteria * Subject aged 18 to 80 * Presence of a mild to moderate impulse control disorder defined by an ECD hyperdopaminergic sub-score (part IV) between 3 and 22 associated with the investigator's assessment * MMSE ≥ 24 * Ongoing treatment with dopaminergic agonist and / or levodopa * No change in antiparkinsonian and / or psychotropic treatment in the month preceding inclusion * Expected stability of antiparkinsonian and / or psychotropic treatment during the study period * Informed patient consent * Patient supported by social security * Presence of a caregiver Exclusion Criteria: * Severe TCI defined by a hyperdopaminergic sub-score at ECMP (part IV) greater than 23 associated with the investigator's assessment * Patient with TCI suspected of having serious legal and / or relationship problems during the study period * Adaptation of the anti-parkinsonian and / or psychotropic treatment (cf section 6.2) probably necessary during the duration of the study * Patient treated with naltrexone, amantadine, antipsychotic in the 6 weeks prior to inclusion * Patient under tutorship or curatorship * History of hypersensitivity to any of the components or to any of the excipients * Fructose intolerance, glucose-galactose malabsorption syndrome or sucrase / isomaltase deficiency * Gastrointestinal duodenal ulcer in progress * Pregnancy, breastfeeding * Patients with contra-indicated treatments in association with NAC * Patient with phenylketonuria * Patients with proven difficulty in expectorating * Patients with an asthmatic risk that can lead to bronchospasm * Patients with intolerance to histamine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Impulse control disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disruptive, Impulse Control, and Conduct Disorders impulse control disorder Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Impulse control disorder Parkinson

Contacts and locations

Locations

  • CHU Amiens Picardie

    Amiens, Picardie, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.